Literature DB >> 25822095

Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.

Tracy J Doyle1, Avignat S Patel1, Hiroto Hatabu2,3, Mizuki Nishino2,3, Guodong Wu4, Juan C Osorio1, Maria F Golzarri1, Andres Traslosheros1, Sarah G Chu1, Michelle L Frits5, Christine K Iannaccone5, Diane Koontz6, Carl Fuhrman7, Michael E Weinblatt5, Souheil Y El-Chemaly1, George R Washko1, Gary M Hunninghake1,8, Augustine M K Choi9, Paul F Dellaripa5, Chester V Oddis6, Nancy A Shadick5, Dana P Ascherman10, Ivan O Rosas1,4.   

Abstract

RATIONALE: Interstitial lung disease (ILD), a leading cause of morbidity and mortality in rheumatoid arthritis (RA), is highly prevalent, yet RA-ILD is underrecognized.
OBJECTIVES: To identify clinical risk factors, autoantibodies, and biomarkers associated with the presence of RA-ILD.
METHODS: Subjects enrolled in Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) and American College of Rheumatology (ACR) cohorts were evaluated for ILD. Regression models were used to assess the association between variables of interest and RA-ILD. Receiver operating characteristic curves were generated in BRASS to determine if a combination of clinical risk factors and autoantibodies can identify RA-ILD and if the addition of investigational biomarkers is informative. This combinatorial signature was subsequently tested in ACR.
MEASUREMENTS AND MAIN RESULTS: A total of 113 BRASS subjects with clinically indicated chest computed tomography scans (41% with a spectrum of clinically evident and subclinical RA-ILD) and 76 ACR subjects with research or clinical scans (51% with a spectrum of RA-ILD) were selected. A combination of age, sex, smoking, rheumatoid factor, and anticyclic citrullinated peptide antibodies was strongly associated with RA-ILD (areas under the curve, 0.88 for BRASS and 0.89 for ACR). Importantly, a combinatorial signature including matrix metalloproteinase 7, pulmonary and activation-regulated chemokine, and surfactant protein D significantly increased the areas under the curve to 0.97 (P = 0.002, BRASS) and 1.00 (P = 0.016, ACR). Similar trends were seen for both clinically evident and subclinical RA-ILD.
CONCLUSIONS: Clinical risk factors and autoantibodies are strongly associated with the presence of clinically evident and subclinical RA-ILD on computed tomography scan in two independent RA cohorts. A biomarker signature composed of matrix metalloproteinase 7, pulmonary and activation-regulated chemokine, and surfactant protein D significantly strengthens this association. These findings may facilitate identification of RA-ILD at an earlier stage, potentially leading to decreased morbidity and mortality.

Entities:  

Keywords:  biomarkers; interstitial lung disease; rheumatoid arthritis; risk prediction; subclinical

Mesh:

Substances:

Year:  2015        PMID: 25822095      PMCID: PMC4476561          DOI: 10.1164/rccm.201411-1950OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  49 in total

1.  Trends in microarray analysis.

Authors:  Robin L Stears; Todd Martinsky; Mark Schena
Journal:  Nat Med       Date:  2003-01       Impact factor: 53.440

2.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

3.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

4.  Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis.

Authors:  J K Dawson; H E Fewins; J Desmond; M P Lynch; D R Graham
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

5.  Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent.

Authors:  H Takahashi; T Fujishima; H Koba; S Murakami; K Kurokawa; Y Shibuya; M Shiratori; Y Kuroki; S Abe
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

6.  Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.

Authors:  K E Greene; T E King; Y Kuroki; B Bucher-Bartelson; G W Hunninghake; L S Newman; H Nagae; R J Mason
Journal:  Eur Respir J       Date:  2002-03       Impact factor: 16.671

Review 7.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

8.  Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis.

Authors:  Jin Woo Song; Kyung Hyun Do; Se Jin Jang; Thomas V Colby; Seungbong Han; Dong Soon Kim
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

9.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.

Authors:  Bartolome R Celli; Claudia G Cote; Jose M Marin; Ciro Casanova; Maria Montes de Oca; Reina A Mendez; Victor Pinto Plata; Howard J Cabral
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

10.  Relationship of rheumatoid factor to lung diffusion capacity in smoking and non-smoking patients with rheumatoid arthritis.

Authors:  R Luukkainen; M Saltyshev; R Pakkasela; E Nordqvist; H Huhtala; M Hakala
Journal:  Scand J Rheumatol       Date:  1995       Impact factor: 3.641

View more
  53 in total

1.  Connective tissue disease associated interstitial pneumonia: a challenge for both rheumatologists and pulmonologists.

Authors:  Sarah Geerts; Wim Wuyts; Ellen De Langhe; Jan Lenaerts; Jonas Yserbyt
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.

Authors:  Md Yuzaiful Md Yusof; Angela Kabia; Michael Darby; Giovanni Lettieri; Paul Beirne; Edward M Vital; Shouvik Dass; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

3.  Baseline Characteristics and Progression of a Spectrum of Interstitial Lung Abnormalities and Disease in Rheumatoid Arthritis.

Authors:  Leticia Kawano-Dourado; Tracy J Doyle; Karina Bonfiglioli; Márcio V Y Sawamura; Renato H Nakagawa; Fábio E Arimura; Hye J Lee; Diana Arrais de Souza Rangel; Cleonice Bueno; Carlos R R Carvalho; Maria Laura Sabbag; Camila Molina; Ivan O Rosas; Ronaldo A Kairalla
Journal:  Chest       Date:  2020-05-16       Impact factor: 9.410

Review 4.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 5.  Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms.

Authors:  Francisco Paulin; Tracy J Doyle; Elaine A Fletcher; Dana P Ascherman; Ivan O Rosas
Journal:  Rev Invest Clin       Date:  2015 Sep-Oct       Impact factor: 1.451

6.  Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.

Authors:  Argyris Tzouvelekis; Jose D Herazo-Maya; Martin Slade; Jen-Hwa Chu; Giuseppe Deiuliis; Changwan Ryu; Qin Li; Koji Sakamoto; Gabriel Ibarra; Hongyi Pan; Mridu Gulati; Danielle Antin-Ozerkis; Erica L Herzog; Naftali Kaminski
Journal:  Respirology       Date:  2016-10-19       Impact factor: 6.424

Review 7.  Lung Manifestations in the Rheumatic Diseases.

Authors:  Tracy J Doyle; Paul F Dellaripa
Journal:  Chest       Date:  2017-05-25       Impact factor: 9.410

Review 8.  The Roles of Cigarette Smoking and the Lung in the Transitions Between Phases of Preclinical Rheumatoid Arthritis.

Authors:  Jeffrey A Sparks; Elizabeth W Karlson
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

Review 9.  Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts.

Authors:  Yoel Brito; Marilyn K Glassberg; Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2017-11-09       Impact factor: 4.592

10.  Visual Assessment of Chest Computed Tomography Findings in Anti-cyclic Citrullinated Peptide Antibody Positive Rheumatoid Arthritis: Is it Associated with Airway Abnormalities?

Authors:  Won Hong Park; Song Soo Kim; Seung Cheol Shim; Seung Taek Song; Sung Soo Jung; Jin Hwan Kim; Namkug Kim; Joon Beom Seo
Journal:  Lung       Date:  2015-11-25       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.